Mathias Rummel

9.3k citations
127 papers · 7k · 1 hit paper · h-index 33

Impact in

  • Hematology top 0.5%
    • Acute Myeloid Leukemia Research
    • Platelet Disorders and Treatments
    • Hematopoietic Stem Cell Transplantation
    • Multiple Myeloma Research and Treatments
    • Lymphoma Diagnosis and Treatment

Papers in

    • Lymphoma Diagnosis and Treatment 64
    • Platelet Disorders and Treatments 16
    • Acute Myeloid Leukemia Research 15
    • Multiple Myeloma Research and Treatments 4
    • Erythropoietin and Anemia Treatment 1

Mathias Rummel

119 papers receiving 6.8k citations

Mathias Rummel's Hit Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial 2013 · 1.2k citations
1.2k0+4+8Years since publication2505007501k

Peers

Mathias Rummel
Comparison fields: 5 of 93
  • Hematology 2.1k
  • Pathology and Forensic Medicine 2.5k
  • Genetics 1k
  • Neurology 387
  • Oncology 361
Replace Kamel Laribi with:
Kamel Laribi France
Nishitha M Reddy United States
Isabelle Bence‐Bruckler Canada
Haifa Kathrin Al‐Ali Germany
Christopher Pocock United Kingdom
Paula V. Marlton Australia
Krzysztof Warzocha Poland
Carolyn Owen Canada
Francisco J. Hernandez‐Ilizaliturri United States
Ercole Brusamolino Italy
Mathias Rummel relative to Kamel Laribi France Kamel Laribi's profile →
Citations per field
00.5×2×3×3.9×
Kamel Laribi · 1×
Citations per year

Countries citing papers authored by Mathias Rummel

Since Specialization
Citations

This map shows the geographic impact of Mathias Rummel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathias Rummel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathias Rummel more than expected).

Fields of papers citing papers by Mathias Rummel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathias Rummel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathias Rummel. The network helps show where Mathias Rummel may publish in the future.

Co-authors

The 25 scholars most cited alongside Mathias Rummel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mathias Rummel Line = papers co-authored together Mathias Rummel links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 127 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Hit paper breakdown →
20131180
2 2010395
3 2009374
4 2005365
5 2010345
6 2017294
7 2013233
8 2016218
9 2009213
10 2018199
11 2004163
12
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
2002159
13 2012151
14 2011145
15 2016145
16 2015134
17 2011132
18 2009129
19 2016129
20 2010122

About Mathias Rummel

Mathias Rummel is a scholar working on Pathology and Forensic Medicine, Hematology, Genetics, Neurology and Oncology, having authored 127 papers that have together received 7k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (64 papers), Chronic Lymphocytic Leukemia Research (21 papers), Platelet Disorders and Treatments (16 papers), Acute Myeloid Leukemia Research (15 papers), Multiple Myeloma Research and Treatments (4 papers), CNS Lymphoma Diagnosis and Treatment (3 papers), Erythropoietin and Anemia Treatment (1 paper) and Protein Tyrosine Phosphatases (1 paper). The work is most often cited by research in Hematology (2.1k citations), Pathology and Forensic Medicine (2.5k citations), Genetics (1k citations), Neurology (387 citations) and Oncology (361 citations). Mathias Rummel has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Dieter F. Hoelzer, Bruce D. Cheson, Eckhart Weidmann, Dorothea Kofahl-Krause, Wolfram Brugger, Ulrich von Grünhagen, Paris Sophokles Mitrou, Heinz Dürk, Juergen Barth and N. Niederle. Their work appears in journals such as Blood, Leukemia, Journal of Clinical Oncology, British Journal of Haematology and Hematological Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact